An inactivation of gut bacteria can reduce the risk of cardiovascular disease

a new study in Belgium has found that taking an inactivate intestinal probiotic can improve metabolism and reduce the risk of cardiovascular disease and type 2 diabetes from obesity.
the bacteria, called mucosal protein Ackermann's bacteria, is one of the main members of the human gut bacterium and was first isolated in 2004. Previous animal experiments have shown that it has the effect of suppressing metabolic diseases such as type 2 diabetes, and that the bacteria is even better at reducing the risk of cardiovascular disease after inactivation than live bacteria.
university in Leuven, Belgium, said in a press release that its researchers conducted the first small-scale human trials using the mucosal protein Ackermann bacteria.
32 overweight or obese volunteers completed the trial, the team said in a paper published in the British journal Nature Medicine. The volunteers were divided into three groups of daily oral live mucosal Ackman bacteria, the bacteria or placebo inactivated by pasteurization, without changing their diet and exercise habits.
results showed that volunteers who took inactivation bacteria after three months were more sensitive to insulin and had lower plasma cholesterol levels, meaning they had a lower risk of cardiovascular disease and type 2 diabetes. The above indicators continued to worsen in the volunteers who took the placebo.
, inactivate bacteria also caused a small decline in the volunteers' weight, body fat and hips, and lowered levels of some inflammatory markers in the liver.
the volunteers were given 10 billion live or inactived bacteria per day, with no side effects after three months of continuous use, and better safety and tolerance. The researchers say this suggests that using the bacteria as a dietary supplement is feasible. (Source: Xinhua.
relevant paper information: